{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T11:08:41Z","timestamp":1794136121997,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s10072-025-08128-4","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T09:59:35Z","timestamp":1742464775000},"page":"3299-3302","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Prominent and fast response to eculizumab in myasthenic crisis: the potential as rescue therapy in refractory myasthenia gravis"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3027-7863","authenticated-orcid":false,"given":"Christian","family":"Messina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Crescimanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"8128_CR1","doi-asserted-by":"publisher","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (May 2019) Myasthenia Gravis. Nat Rev Dis Primers 5(1):30. https:\/\/doi.org\/10.1038\/s41572-019-0079-y","DOI":"10.1038\/s41572-019-0079-y"},{"key":"8128_CR2","doi-asserted-by":"publisher","unstructured":"Claytor B, Cho S, Li Y (2023) Myasthenic crisis, Muscle Nerve, vol. 68, no. 1, pp. 8\u201319, Jul. https:\/\/doi.org\/10.1002\/mus.27832","DOI":"10.1002\/mus.27832"},{"key":"8128_CR3","doi-asserted-by":"publisher","unstructured":"Howard JF et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study, Lancet Neurol, vol. 16, no. 12, pp. 976\u2013986, Dec. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"8128_CR4","doi-asserted-by":"publisher","unstructured":"Xiao H, Wu K, Liang X, Li R, Lai KP (2021) Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis, Front Immunol, vol. 12, Aug. https:\/\/doi.org\/10.3389\/fimmu.2021.715036","DOI":"10.3389\/fimmu.2021.715036"},{"key":"8128_CR5","doi-asserted-by":"publisher","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S (2021) The use of eculizumab in ventilator-dependent myasthenia gravis patients, Muscle Nerve, vol. 64, no. 2, pp. 212\u2013215, Aug. https:\/\/doi.org\/10.1002\/mus.27326","DOI":"10.1002\/mus.27326"},{"key":"8128_CR6","doi-asserted-by":"publisher","unstructured":"Strano CMM, Sorrenti B, Bosco L, Falzone YM, Fazio R, Filippi M (2022) Eculizumab as a fast-acting rescue therapy in a refractory myasthenic crisis: a case report, J Neurol, vol. 269, no. 11, pp. 6152\u20136154, Nov. https:\/\/doi.org\/10.1007\/s00415-022-11222-8","DOI":"10.1007\/s00415-022-11222-8"},{"key":"8128_CR7","doi-asserted-by":"publisher","unstructured":"Song J et al (Jan. 2024) The safety and efficacy profile of Eculizumab in myasthenic crisis: a prospective small case series. Ther Adv Neurol Disord 17. https:\/\/doi.org\/10.1177\/17562864241261602","DOI":"10.1177\/17562864241261602"},{"key":"8128_CR8","doi-asserted-by":"publisher","unstructured":"Yeo CJJ, Pleitez MY (Aug. 2018) Eculizumab in refractory myasthenic crisis. Muscle Nerve 58(2). https:\/\/doi.org\/10.1002\/mus.26124","DOI":"10.1002\/mus.26124"},{"key":"8128_CR9","doi-asserted-by":"publisher","unstructured":"Vinciguerra C et al (Oct. 2023) Starting Eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci 44(10):3707\u20133709. https:\/\/doi.org\/10.1007\/s10072-023-06900-y","DOI":"10.1007\/s10072-023-06900-y"},{"key":"8128_CR10","doi-asserted-by":"publisher","unstructured":"Menacher M, Ellssel M, Kwiedor I, Naumann M, Bayas A (Jan. 2024) Complement Inhibition in seropositive generalized myasthenia Gravis as rescue therapy in impending and effective treatment in frequently recurring impending myasthenic crisis\u2014a case series. Ther Adv Neurol Disord 17. https:\/\/doi.org\/10.1177\/17562864241301361","DOI":"10.1177\/17562864241301361"},{"key":"8128_CR11","doi-asserted-by":"publisher","unstructured":"Wijnsma KL et al (Jul. 2019) Pharmacology, pharmacokinetics and pharmacodynamics of Eculizumab, and possibilities for an individualized approach to Eculizumab. Clin Pharmacokinet 58(7):859\u2013874. https:\/\/doi.org\/10.1007\/s40262-019-00742-8","DOI":"10.1007\/s40262-019-00742-8"},{"key":"8128_CR12","doi-asserted-by":"publisher","unstructured":"Pane C et al (Sep. 2024) A real-life experience with Eculizumab and Efgartigimod in generalized myasthenia Gravis patients. J Neurol 271(9):6209\u20136219. https:\/\/doi.org\/10.1007\/s00415-024-12588-7","DOI":"10.1007\/s00415-024-12588-7"},{"key":"8128_CR13","doi-asserted-by":"publisher","unstructured":"Kim S, Lee J-J, Seok HY (2023) Eculizumab as a promising rescue therapy for acute exacerbations of myasthenia gravis, Neurological Sciences, vol. 44, no. 12, pp. 4573\u20134574, Dec. https:\/\/doi.org\/10.1007\/s10072-023-06993-5","DOI":"10.1007\/s10072-023-06993-5"},{"key":"8128_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-024-07861-6","author":"D Ricciardi","year":"2024","unstructured":"Ricciardi D, Erra C, Tuccillo F, De Martino BM, Fasolino A, Habetswallner F (2024) Eculizumab in refractory myasthenia Gravis: a real-world single-center experience. Neurol Sci Nov. https:\/\/doi.org\/10.1007\/s10072-024-07861-6","journal-title":"Neurol Sci Nov"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08128-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-025-08128-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-025-08128-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T04:45:42Z","timestamp":1749530742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-025-08128-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["8128"],"URL":"https:\/\/doi.org\/10.1007\/s10072-025-08128-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"20 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Verbal informed consent was obtained for anonymized patient information to be published in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors did not receive support from any organization for the submitted work.The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and Declarations"}}]}}